Page 18 - TD-4-1

Tumor Discovery EpCAM-targeting cancer immunotherapies

of Science and Technology administered through the doi: 10.15698/cst2019.06.188
National Research Foundation of South Africa (Grant 8. Lei Z, Liu W, Nie Y, Yang Y, Chen G, Huang L. EpCAM
Number 47904). is essential to maintaining the immune homeostasis of
intestines via keeping the expression of pIgR in the intestinal
Conflict of interest epithelium of mice. Front Immunol. 2022;13:1-15.
The authors declare no conflicts of interest. doi: 10.3389/fimmu.2022.843378

Author contributions 9. Siddiqui H, Rawal P, Bihari C, Arora N, Kaur S. Vascular
endothelial growth factor promotes proliferation of epithelial
Conceptualization: Dennis Makafui Dogbey, Stefan Barth cell adhesion molecule-positive cells in nonalcoholic
Writing–original draft: Dennis Makafui Dogbey, Ursula- steatohepatitis. J Clin Exp Hepatol. 2020;10:275-283.
Claire Andong-Koung-Edzidzi, Gomolemo Atlegang doi: 10.1016/j.jceh.2019.11.011
Molope, Jesmika Singh, Tatenda Lovemore Bvudzijena
Writing–review & editing: Krupa Naran, Stefan Barth 10. Schwartzberg LS. Clinical experience with edrecolomab:
A monoclonal antibody therapy for colorectal carcinoma.
Ethics approval and consent to participate Crit Rev Oncol Hematol. 2001;40:17-24.
doi: 10.1016/S1040-8428(01)00131-7
Not applicable.
11. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone
Consent for publication or in combination with fluorouracil and folinic acid in the
adjuvant treatment of stage III colon cancer: A randomised
Not applicable. study. Lancet. 2002;360:671-677.
Availability of data doi: 10.1016/S0140-6736(02)09836-7

Not applicable. 12. Oberneder R, Weckermann D, Ebner B, et al. A phase I study
with adecatumumab, a human antibody directed against
References epithelial cell adhesion molecule, in hormone refractory
prostate cancer patients. Eur J Cancer. 2006;42:2530-2538.
1. Satofuka H, Wang Y, Yamazaki K, et al. Characterization
of human anti - EpCAM antibodies for developing an doi: 10.1016/j.ejca.2006.05.029
antibody - drug conjugate. Sci Rep. 2023;13:4225. 13. Autio KA, Boni V, Humphrey RW, Naing A. Probody
doi: 10.1038/s41598-023-31263-x therapeutics: An emerging class of therapies designed to
enhance on-target effects with reduced off-tumor toxicity for
2. Pavšič M, Gunčar G, Djinovi-Carugo K, Lenarčič B. Crystal use in immuno-oncology. Clin Cancer Res. 2020;26:984-989.
structure and its bearing towards an understanding of key
biological functions of EpCAM. Nat Commun. 2014;5:4764. doi: 10.1158/1078-0432.CCR-19-1457
doi: 10.1038/ncomms5764 14. Zheng X, Wu Y, Bi J, et al. The use of supercytokines,
immunocytokines, engager cytokines, and other synthetic
3. Mitra M, Kandalam M, Verma RS, Umamaheswari K. cytokines in immunotherapy. Cell Mol Immunol.
Genome-wide changes accompanying the knockdown of 2022;19:192-209.
Ep-CAM in retinoblastoma. Mol Vis. 2010;16:828-842.
doi: 10.1038/s41423-021-00786-6
4. Nagao K, Zhu J, Heneghan MB, et al. Abnormal placental
development and early embryonic lethality in EpCAM-Null 15. Neri D, Sondel PM. Immunocytokines for cancer treatment:
mice. PLoS One. 2009;4:e8543. Past, present and future immunocytokine formats Europe
PMC Funders Group. Curr Opin Immunol. 2016;40:96-102.
doi: 10.1371/journal.pone.0008543
doi: 10.1016/j.coi.2016.03.006.Immunocytokines
5. Imrich S, Hachmeister M, Gires O. EpCAM and its potential
role in tumor-initiating cells. Cell Adh Migr. 2012;6:30-38. 16. Ko YJ, Bubley GJ, Weber R, et al. Safety, pharmacokinetics,
and biological pharmacodynamics of the immunocytokine
doi: 10.4161/cam.18953 EMD 273066 (huKS-IL2). J Immunother. 2004;27:232-239.
6. Schnell U, Kuipers J, Giepmans BN. EpCAM proteolysis: New doi: 10.1097/00002371-200405000-00008
fragments with distinct functions? Biosci Rep. 2013;33:321-332.
17. Connor JP, Lewis NL. A phase 1b study of humanized
doi: 10.1042/BSR20120128 KS-interleukin-2 (huKS-IL2) immunocytokine with
7. Keller L, Werner S, Pantel K. Biology and clinical relevance cyclophosphamide in patients with EpCAM-positive
of EpCAM. Cell Stress. 2019;3:165-180. advanced solid tumors. BMC Cancer. 2013;13:20.

Volume 4 Issue 1 (2025) 10 doi: 10.36922/td.4926